PMC:7216762 / 6781-7229
Annnotations
LitCovid-PD-MONDO
| Id | Subject | Object | Predicate | Lexical cue | mondo_id |
|---|---|---|---|---|---|
| T18 | 226-234 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T19 | 359-367 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
LitCovid-PD-CHEBI
| Id | Subject | Object | Predicate | Lexical cue | chebi_id |
|---|---|---|---|---|---|
| T8 | 207-211 | Chemical | denotes | drug | http://purl.obolibrary.org/obo/CHEBI_23888 |
| T9 | 271-275 | Chemical | denotes | drug | http://purl.obolibrary.org/obo/CHEBI_23888 |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T48 | 0-448 | Sentence | denotes | The Italian Drug Association (AIFA) and Gilead have recently announced that Italy will take part in two Phase III clinical trials that will allow an assessment of the efficacy and safety of the experimental drug Remdesivir in COVID-19 patients.5 As mentioned above, this drug is currently being administered “for compassionate use” for emergency treatment of COVID-19 patients in critical condition that do not have alternative therapeutic options. |
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
|---|---|---|---|---|---|
| 61 | 235-243 | Species | denotes | patients | Tax:9606 |
| 62 | 368-376 | Species | denotes | patients | Tax:9606 |
| 63 | 212-222 | Chemical | denotes | Remdesivir | MESH:C000606551 |
| 64 | 226-234 | Disease | denotes | COVID-19 | MESH:C000657245 |
| 65 | 359-367 | Disease | denotes | COVID-19 | MESH:C000657245 |